Meeting
2024 ASCO Genitourinary Cancers Symposium
Impact of homologous recombination repair (HRR) or nucleotide excision repair (NER) deficiency on sensitivity to antibody drug conjugate (ADC) payloads in urothelial cancer.
Authors
Surish P Shanmugam
Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA
Surish P Shanmugam , Yuzhen Zhou , Vincent D'Andrea , Timothy Hanlon , Raie Bekele , Zoltan Szallasi , Joaquim Bellmunt , Kent William Mouw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 665)
DOI
10.1200/JCO.2024.42.4_suppl.665
Abstract #
665
Poster Bd #
K9
Abstract Disclosures
Similar Posters
First Author: Elena Castro
Poster
2024 ASCO Annual Meeting
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
First Author: Rachel Occhiogrosso Abelman
Poster
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
First Author: David Joseph Benjamin
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran